GLP-1 Drugs Like Ozempic Linked to Gallstones and Acid Reflux in Major Review
Meta-analysis of 106,395 patients reveals GLP-1 receptor agonists increase risk of gallstones by 46% and GERD by 119%.
157 articles in this topic
Meta-analysis of 106,395 patients reveals GLP-1 receptor agonists increase risk of gallstones by 46% and GERD by 119%.
New research reveals how obesity triggers chronic inflammation and how GLP-1 medications provide anti-inflammatory benefits independent of weight loss.
New research explores how GLP-1-based drugs like Ozempic and Wegovy work to treat obesity beyond simple appetite suppression.
Researchers discover how disrupted circadian rhythms in fat cells impair mitochondrial function, leading to metabolic syndrome.
Machine learning analyzes glucose patterns to identify distinct metabolic subphenotypes in type 2 diabetes patients.
New study shows DunedinPACE aging biomarker can predict who will develop metabolic syndrome years in advance, outperforming other epigenetic clocks.
Expert consensus provides updated recommendations for managing popular weight-loss medications before and after surgery.
New review explains the dual mechanisms behind GLP-1 receptor agonists' dramatic weight loss effects in both central and peripheral systems.
Meta-analysis reveals patients regain substantial weight after discontinuing semaglutide, tirzepatide, and liraglutide therapy.
New research reveals how maltol, a widely used food flavoring, may weaken bones in diabetic patients by disrupting bone remodeling.
New review reveals how saturated fat-rich diets trigger neuroinflammation and cognitive decline, but offers actionable prevention strategies.
New research shows combining weight-loss medications with hormone therapy could transform health outcomes for obese men with low testosterone.